

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

**SECTION 1. IDENTIFICATION**

Product identifier : Ezetimibe / Simvastatin Formulation

**Manufacturer or supplier's details**

Company : Organon & Co.

Address : Rua Treze de Maio, 1161  
Campinas, São Paulo, Brazil 13106-054

Telephone : +1 551-430-6000 US | +55 (19) 3758-2000 BR

Emergency telephone : For 24/7 emergency response advice, call CHEMTREC at +55 11 4349-1359 (local) or 0800 892 0479 (toll-free). Global 24/7: +1-800-424-9300 (United States, English only).

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification in accordance with ABNT NBR 14725 Standard**

Skin irritation : Category 2

Skin sensitization : Category 1

Specific target organ toxicity - repeated exposure : Category 1 (Liver, muscle, optic nerve, Eyes)

Short-term (acute) aquatic hazard : Category 3

Long-term (chronic) aquatic hazard : Category 2

**GHS label elements in accordance with ABNT NBR 14725 Standard**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H315 Causes skin irritation.  
H317 May cause an allergic skin reaction.  
H372 Causes damage to organs (Liver, muscle, optic nerve, Eyes) through prolonged or repeated exposure.

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

H402 Harmful to aquatic life.  
H411 Toxic to aquatic life with long lasting effects.

**Precautionary Statements**

:

**Prevention:**

P260 Do not breathe dust.  
P264 Wash skin thoroughly after handling.  
P273 Avoid release to the environment.  
P280 Wear protective gloves.

**Response:**

P302 + P352 IF ON SKIN: Wash with plenty of water.  
P314 Get medical advice/ attention if you feel unwell.  
P391 Collect spillage.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.  
May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Cellulose	9004-34-6		>= 10 -< 20
Ezetimibe	163222-33-1	Aquatic Chronic, 1	>= 10 -< 20
Simvastatin	79902-63-9	Skin Irrit., 2 Skin Sens., 1 STOT RE, (Liver, muscle, optic nerve, Eyes) , 1 Aquatic Acute, 2 Aquatic Chronic, 2	>= 10 -< 20
Magnesium stearate	557-04-0		>= 1 -< 5

**SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

	and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Dust contact with the eyes can lead to mechanical irritation. Causes skin irritation. May cause an allergic skin reaction. Causes damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO <sub>x</sub> ) Fluorine compounds Metal oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protection	: Use personal protective equipment.
----------------------------------	--------------------------------------

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

tive equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**SECTION 7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.  
Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Contaminated work clothing should not be allowed out of the workplace.

## Ezetimibe / Simvastatin Formulation

Version 7.2      Revision Date: 2025/07/01      SDS Number: 300000000598      Date of last issue: 2023/09/30  
 Date of first issue: 2014/11/04

Wash contaminated clothing before re-use.  
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.  
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Self-reactive substances and mixtures  
 Organic peroxides  
 Explosives  
 Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
Ezetimibe	163222-33-1	TWA	25 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Simvastatin	79902-63-9	TWA	25 µg/m <sup>3</sup> (OEB 3)	Internal
Further information: DSEN				
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Physical state	:	powder
Color	:	No data available
Odor	:	No information available.
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: No data available
Autoignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: Not applicable
Particle characteristics	
Particle size	: Not applicable

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure	: Inhalation Skin contact Ingestion Eye contact
--	--

**Acute toxicity**

Based on available data, the classification criteria are not met.

**Components:****Cellulose:**

Acute oral toxicity	: LD50 (Rat): > 5.000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 5,8 mg/l

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

---

Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

**Ezetimibe:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg  
LD50 (Dog): > 3.000 mg/kg  
LD50 (Mouse): > 5.000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 2.000 mg/kg  
Application Route: Intraperitoneal  
LD50 (Mouse): > 1.000 - < 2.000 mg/kg  
Application Route: Intraperitoneal

**Simvastatin:**

Acute oral toxicity : LD50 (Rat): 5.000 mg/kg  
LD50 (Mouse): 3.800 mg/kg

**Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg  
Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****Ezetimibe:**

Species : Rabbit  
Result : No skin irritation

**Simvastatin:**

Species : Rabbit  
Remarks : Moderate skin irritation



**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

---

**Magnesium stearate:**

Species	:	Rabbit
Result	:	No skin irritation
Remarks	:	Based on data from similar materials

**Serious eye damage/eye irritation**

Based on available data, the classification criteria are not met.

**Components:****Ezetimibe:**

Species	:	Rabbit
Result	:	No eye irritation

**Simvastatin:**

Species	:	Rabbit
Remarks	:	slight irritation

**Magnesium stearate:**

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

**Respiratory or skin sensitization****Skin sensitization**

May cause an allergic skin reaction.

**Respiratory sensitization**

Based on available data, the classification criteria are not met.

**Components:****Ezetimibe:**

Test Type	:	Maximization Test
Species	:	Guinea pig
Result	:	negative

Test Type	:	Respiratory sensitization
Remarks	:	Not classified due to lack of data.

**Simvastatin:**

Test Type	:	Skin sensitization
Assessment	:	Probability or evidence of skin sensitization in humans
Result	:	positive

Test Type	:	Respiratory sensitization
Remarks	:	No data available

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

**Magnesium stearate:**

Test Type	: Maximization Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative
Remarks	: Based on data from similar materials

**Germ cell mutagenicity**

Based on available data, the classification criteria are not met.

**Components:****Cellulose:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay Result: negative
	Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

**Ezetimibe:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay Metabolic activation: with and without metabolic activation Result: negative
	Test Type: Chromosomal aberration Test system: Human lymphocytes Result: negative
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

**Simvastatin:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay Result: negative
	Test Type: Alkaline elution assay Result: negative

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

---

Test Type: Chromosomal aberration

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo

: Test Type: Micronucleus test

Species: Mouse

Application Route: Oral

Result: negative

Germ cell mutagenicity -  
Assessment: Weight of evidence does not support classification as a germ  
cell mutagen.**Magnesium stearate:**

Genotoxicity in vitro

: Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay

Result: negative

Remarks: Based on data from similar materials

**Carcinogenicity**

Based on available data, the classification criteria are not met.

**Components:****Cellulose:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 72 weeks
Result	: negative

**Ezetimibe:**

Species	: Rat, female
Application Route	: oral (feed)
Exposure time	: 104 weeks
Result	: negative

Species	: Rat, male
Application Route	: oral (feed)
Exposure time	: 104 weeks
Result	: negative

Species	: Mouse
---------	---------

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

**Simvastatin:**

Species : Mouse  
Application Route : Oral  
Exposure time : < 92 weeks  
Target Organs : Harderian gland  
Tumor Type : Liver, Lungs  
Remarks : The significance of these findings for humans is not certain.

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Tumor Type : Liver, Thyroid  
Remarks : The significance of these findings for humans is not certain.

**Reproductive toxicity**

Based on available data, the classification criteria are not met.

**Components:****Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Ezetimibe:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Fertility: NOAEL: > 1.000 mg/kg body weight  
Result: No effects on fertility., No fetotoxicity.

Effects on fetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight  
Result: No adverse effects.

Test Type: Development  
Species: Rabbit

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

---

Application Route: Oral  
Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight  
Result: No adverse effects.

Reproductive toxicity - Assessment : Weight of evidence does not support classification for reproductive toxicity

**Simvastatin:**

Effects on fertility : Test Type: Fertility  
Species: Rat, male  
Application Route: Oral  
Fertility: LOAEL: 25 mg/kg body weight

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Embryo-fetal toxicity.: NOAEL: 25 mg/kg body weight  
Result: No teratogenic effects., No adverse effects.

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-fetal toxicity.: NOAEL: 10 mg/kg body weight  
Result: No teratogenic effects., No adverse effects.

Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Embryo-fetal toxicity.: LOAEL: 60 mg/kg body weight  
Result: Teratogenic potential.  
Remarks: Based on data from similar materials

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**STOT-single exposure**

Based on available data, the classification criteria are not met.

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

---

**Components:****Ezetimibe:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**Simvastatin:**

Remarks : No data available

**STOT-repeated exposure**

Causes damage to organs (Liver, muscle, optic nerve, Eyes) through prolonged or repeated exposure.

**Components:****Ezetimibe:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**Simvastatin:**

Target Organs : Liver, muscle, optic nerve, Eyes  
Assessment : Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Cellulose:**

Species : Rat  
NOAEL :  $\geq 9.000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Ezetimibe:**

Species : Dog  
NOAEL : 1.000 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 1.500 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 500 mg/kg  
Application Route : Oral

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

---

Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 300 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Remarks : No significant adverse effects were reported

**Simvastatin:**

Species : Rat  
NOAEL : 5 mg/kg  
LOAEL : 30 mg/kg  
Application Route : Oral  
Exposure time : 14 - 104 Weeks  
Target Organs : Liver, Testes, Musculo-skeletal system, Eyes

Species : Dog  
LOAEL : 10 mg/kg  
Application Route : Oral  
Exposure time : 14 - 104 Weeks  
Target Organs : Liver, Testes, Eyes

Species : Rabbit  
NOAEL : 30 mg/kg  
LOAEL : 50 mg/kg  
Application Route : Oral  
Target Organs : Liver, Kidney

**Magnesium stearate:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

**Aspiration toxicity**

Based on available data, the classification criteria are not met.

**Components:****Ezetimibe:**

Not applicable

**Simvastatin:**

Not applicable

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

**Experience with human exposure****Components:****Ezetimibe:**

Ingestion : Symptoms: headache, nausea, Vomiting, diarrhea, flatulence, muscle pain, upper respiratory tract infection, back pain, joint pain

**Simvastatin:**

Skin contact : Remarks: May produce an allergic reaction.  
Ingestion : Target Organs: Liver  
Symptoms: upper respiratory tract infection, headache, abdominal pain, constipation, nausea  
Target Organs: Musculo-skeletal system

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
Exposure time: 96 h  
Remarks: Based on data from similar materials

**Ecotoxicology Assessment**

Acute aquatic toxicity : No toxicity at the limit of solubility.

**Ezetimibe:**

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 0,125 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 4 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): > 0,317 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

NOEC (*Pseudokirchneriella subcapitata* (green algae)): 0,317 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.



**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

---

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0,051 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210

NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l  
Exposure time: 7 d  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0,282 mg/l  
Exposure time: 21 d  
Remarks: No toxicity at the limit of solubility.

M-Factor (Chronic aquatic toxicity) : 1

Toxicity to microorganisms : EC50: > 4,4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.

NOEC: 4,4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.

**Simvastatin:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 2,91 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 3,5 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 25 mg/l  
Exposure time: 96 h

NOEC (Pseudokirchneriella subcapitata (green algae)): 25 mg/l  
Exposure time: 96 h

Toxicity to microorganisms : EC50: > 30 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 21 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

---

Method: OECD Test Guideline 209

**Magnesium stearate:**

Toxicity to fish : LC50 (*Leuciscus idus* (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (*Daphnia magna* (Water flea)): > 1 mg/l  
Exposure time: 48 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (*Pseudokirchneriella subcapitata* (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.

NOELR (*Pseudokirchneriella subcapitata* (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (*Pseudomonas putida*): > 100 mg/l  
Exposure time: 16 h  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Ezetimibe:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 6,8 %  
Exposure time: 28 d

Stability in water : Hydrolysis: 50 % (4,5 d)  
Method: OECD Test Guideline 111

**Simvastatin:**

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

Biodegradability : Result: rapidly degradable

Stability in water : Hydrolysis: 50 %(3,2 d)

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****Ezetimibe:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 173  
Exposure time: 97 d  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4,36

**Simvastatin:**

Partition coefficient: n-octanol/water : log Pow: > 4,07

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil****Components:****Ezetimibe:**

Distribution among environmental compartments : log Koc: 4,35  
Method: OECD Test Guideline 106

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number	: UN 3077
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)
Class	: 9
Packing group	: III
Labels	: 9
Environmentally hazardous	: yes

**IATA-DGR**

UN/ID No.	: UN 3077
Proper shipping name	: Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Simvastatin)
Class	: 9
Packing group	: III
Labels	: Miscellaneous Dangerous Goods
Packing instruction (cargo aircraft)	: 956
Packing instruction (passenger aircraft)	: 956
Environmentally hazardous	: yes

**IMDG-Code**

UN number	: UN 3077
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)
Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****ANTT**

UN number	: UN 3077
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Simvastatin)
Class	: 9
Packing group	: III
Labels	: 9
Hazard Identification Number	: 90

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**SECTION 16. OTHER INFORMATION**

Revision Date : 2025/07/01  
Date format : yyyy/mm/dd

**Further information**

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemi-

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
7.2	2025/07/01	300000000598	Date of first issue: 2014/11/04

---

cal Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

BR / EN